Board committees

Board of Directors:

Michael Wolff Jensen

Chairman

Board member as well as chairman since 2013
Born 1971

Education: Master of Laws (LL.M.), University of Copenhagen

Other current activities: Other current activities: Chairman of the Board in Ascendis Pharma A/S and Chairman of the Board as well as owner of MWJ Partners ApS

Other board assignments (the recent 5 years): Chairman of the Board in Eurocines Vaccines AB and VANX ApS

Holdings: 33,700 shares through MWJ Partners ApS

Independent in relation to the Company and its management and in relation to major shareholders

Maris Hartmanis

Board member

Board member since 2015
Born 1953

Education: Dr. of Technology and Associate Professor, Royal Institute of Technology

Other current activities: Other current activities: CEO and Chairman of the Board in Hartmanis & Partners AB as well as board member in BioLamina

Other current assignments: Board member in Xbrane Biopharma AB

Holdings: 26,494 shares

Independent in relation to the Company and its management and in relation to major shareholders

Gunnar Gårdemyr

Board member

Board member since 2019
Born 1959

Education: BSc Economy, University of Lund

Other current activities: Other current assignments: Chairman of the Board in Rhovac AB, member of the Board in Iconovo AB and Asgard Therapeutics as well as CBO in Follicum AB

Other board assignments (the recent 5 years): VD Targovax AS, Norge

Holdings: 4400 shares

Independent in relation to the Company and its management and in relation to major shareholders

Torbjörn Koivisto

Board member

Board member since 2017
Born 1969

Education: Master of Laws (LL.M.), University of Uppsala

Other current activities: Other current activities: Board member of Hemcheck Sweden AB, Cinclus Pharma Holding AB and IARU Institutet för Affärsjuridisk Rådgivning I Uppsala AB, partner in KOL Arts & Craft Handelsbolag as well as deputy of RJC Roger Johansson Consulting AB

Holdings: 4,000 shares via company (IARU)

Independent in relation to the Company and its management and in relation to major shareholders

Christine Lind

Board member

Board member since 2019
Born 1974

Education: Bachelors in Science in Finance and information Systems, New York University, Masters in Business Administration in Finance and Management, Columbia Business School

Other current activities: Other current activities: Chairman and CEO of Lind Growth Strategy AB, Strategic Advisor of BioArctic AB and board member of Shinka Life Sciences AB

Other board assignments (the recent 5 years): VP Business Development of LifeCell Corporation, EVP Strategic Business Development of Medivir AB and CEO of Medivir AB

Holdings: 4000 shares

Independent in relation to the Company and its management and in relation to major shareholders

Carl-Johan Spak

Board member

Board member since 2015
Born 1956

Education: Dr. of Odontology, Degree in Dentistry, Karolinska Institutet

Other current activities: Other current assignment: Board member of Pharmacolog in Uppsala AB, Symcel Sverige AB, Empros Pharma AB, Inject Pharma Sweden AB, Prokarium Ltd, Synthonics Inc, Kahr Medical Ltd, Sweden-BIO Service AB, Binx Health Ltd, UK, and Bostadsrättsföreningen Smultronhyllan and member of board as well as CEO of Recipharm Venture Fund AB.

Holdings: None

Independent in relation to the Company and its management and in relation to major shareholders

Committees:

Audit Committee

  • Maris Hartmanis, Chairman
  • Christine Lind
  • Carl-Johan Spak

Remuneration Committee

  • Michael Wolff Jensen, Chairman
  • Gunnar Gårdemyr
  • Torbjörn Koivisto